HUTCHMED China Ltd (HCM.L)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Company Info
Highlights
£1.98B
-£0.04
£305.68M
£125.55M
-£21.27M
£206.00 - £353.00
£405.54
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in HUTCHMED China Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
HUTCHMED China Ltd had a return of -1.28% year-to-date (YTD) and 2.20% in the last 12 months. Over the past 10 years, HUTCHMED China Ltd had an annualized return of 6.82%, while the S&P 500 had an annualized return of 11.31%, indicating that HUTCHMED China Ltd did not perform as well as the benchmark.
HCM.L
-1.28%
-0.43%
-15.02%
2.20%
-10.23%
6.82%
^GSPC (Benchmark)
4.46%
2.46%
9.31%
23.49%
13.03%
11.31%
Monthly Returns
The table below presents the monthly returns of HCM.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.60% | -1.28% | |||||||||||
| 2024 | -30.53% | 21.31% | 12.16% | 11.21% | -0.84% | -6.44% | 8.70% | -12.67% | 12.60% | -3.05% | -5.94% | -12.64% | -16.96% |
| 2023 | 10.61% | -4.11% | -21.43% | 14.32% | -23.18% | -2.17% | 18.12% | 6.61% | 16.91% | 14.65% | -4.39% | -7.21% | 7.20% |
| 2022 | -22.17% | -0.85% | -28.48% | -16.07% | -32.95% | 21.51% | 4.37% | 4.43% | -25.23% | -6.99% | 45.12% | 20.00% | -50.19% |
| 2021 | -2.17% | -5.56% | -4.24% | 3.93% | -2.84% | 35.77% | 6.63% | -7.73% | -1.28% | -19.28% | 17.49% | 3.11% | 15.22% |
| 2020 | -0.79% | -6.63% | -13.64% | 11.51% | 3.24% | 25.71% | -9.09% | 22.50% | 0.00% | -8.47% | 2.34% | 0.22% | 21.05% |
| 2019 | -3.43% | 12.43% | 21.97% | -0.97% | -2.61% | -19.46% | -5.56% | 4.56% | -19.83% | 8.77% | 19.68% | 2.43% | 8.57% |
| 2018 | -7.50% | -8.30% | -15.79% | 20.00% | -12.71% | 9.55% | 3.92% | -4.82% | 5.18% | 1.78% | 7.00% | -32.69% | -37.50% |
| 2017 | -2.97% | -4.99% | 55.44% | -8.76% | 6.07% | 14.77% | -6.23% | 12.25% | 5.85% | 14.53% | 9.71% | 10.73% | 146.70% |
| 2016 | -20.52% | -0.23% | -14.69% | -10.99% | 11.16% | 1.34% | -0.00% | -3.17% | -1.36% | 5.26% | 15.51% | 3.30% | -18.64% |
| 2015 | 2.67% | -5.72% | -2.57% | 35.85% | 9.72% | -16.46% | 5.61% | 3.01% | -1.11% | 41.55% | 8.66% | 2.20% | 98.58% |
| 2014 | 1.93% | 30.04% | -3.65% | 1.26% | 6.54% | 6.14% | 10.74% | 9.45% | 8.18% | 1.26% | 25.31% | -6.95% | 126.43% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HCM.L is 45, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for HUTCHMED China Ltd (HCM.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the HUTCHMED China Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the HUTCHMED China Ltd was 85.93%, occurring on Dec 16, 2008. Recovery took 276 trading sessions.
The current HUTCHMED China Ltd drawdown is 62.82%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -85.93% | May 22, 2006 | 448 | Dec 16, 2008 | 276 | Mar 25, 2010 | 724 |
| -78.45% | Jul 23, 2021 | 316 | Oct 24, 2022 | — | — | — |
| -56.2% | Jan 4, 2018 | 559 | Mar 18, 2020 | 338 | Jul 21, 2021 | 897 |
| -53.66% | Nov 10, 2010 | 274 | Dec 16, 2011 | 338 | Apr 30, 2013 | 612 |
| -40.74% | Dec 8, 2015 | 99 | Apr 29, 2016 | 223 | Mar 16, 2017 | 322 |
Volatility
Volatility Chart
The current HUTCHMED China Ltd volatility is 13.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for HUTCHMED China Ltd.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |